Coagulation factor viia (recombinant)-jncw - Biologic Drug Details

Summary for coagulation factor viia (recombinant)-jncw

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for coagulation factor viia (recombinant)-jncw Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for coagulation factor viia (recombinant)-jncw Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for coagulation factor viia (recombinant)-jncw Derived from Patent Text Search

No patents found based on company disclosures

Coagulation Factor VIIa (Recombinant) — Market Dynamics and Financial Trajectory

Last updated: February 26, 2026

What Is the Current Market Landscape for Recombinant Coagulation Factor VIIa?

Recombinant coagulation factor VIIa (rFVIIa), marketed primarily as JNCW, is approved for use in bleeding disorders such as hemophilia with inhibitors. The global market size stood at approximately $725 million in 2022, with a compound annual growth rate (CAGR) projected around 7.4% through 2028. Key market drivers include increasing prevalence of hemophilia, expanded indications, and technological advances in recombinant protein production.

Major companies involved include Novo Nordisk, BPL, and Swedish Orphan Biovitrum. Novo Nordisk's NovoSeven RT (recombinant activated factor VII) remains dominant, holding roughly 55% of the market share globally as of 2022. The product is available in multiple regions, including North America, Europe, and select Asian markets.

What Are the Key Factors Influencing Market Growth?

Prevalence of Hemophilia and Bleeding Disorders

• Hemophilia A and B affect roughly 1 in 5,000 male births.
• Patients with inhibitors to standard factor concentrates rely on rFVIIa for bleeding control.
• Estimated global patient population exceeds 40,000, expanding with increased diagnosis rates.

Regulatory Approvals and Indications Expansion

• Approved for bleeding episodes and surgical prophylaxis.
• Some regions have approved extended indications, such as traumatology and bleeding following cardiac surgery.
• Regulatory bodies are increasingly accommodating orphan drugs, facilitating market access.

Technological and Manufacturing Advances

• Recombinant DNA technology improves purity and reduces infectious risks.
• Newer formulations with higher bioavailability and longer half-life are under development.
• Biotech firms are optimizing production processes, reducing costs.

Competitive Landscape and Patent Dynamics

• Novo Nordisk's patents for NovoSeven RT expire post-2028, opening opportunities for biosimilars.
• Biosimilar development has accelerated since 2020, with candidates demonstrating comparable efficacy and safety.
• Market entry of biosimilars could erode premium pricing and impact revenue streams.

Pricing and Reimbursement Policies

• High treatment costs (per dose approximately $8,000–$12,000) restrict access in low-income countries.
• Reimbursement policies in developed markets influence sales volume.
• Emerging markets show rapid adoption due to government initiatives to improve hemophilia care.

What Are the Financial Trajectories and Revenue Outlooks?

Historical Revenue Performance

Year	Revenue (USD millions)	Growth Rate (%)
2018	480	5.2
2019	510	6.3
2020	565	10.8
2021	655	15.9
2022	725	10.7

Companies benefit from increasing adoption rates, particularly in emerging markets. Novo Nordisk's sales from NovoSeven RT grew at an average CAGR of 8.2% from 2018 to 2022.

Future Revenue Projections

Regional dynamics, patent expiry, and biosimilar entry influence projections:

• 2023-2028 CAGR: Estimated at 7.4%, driven by rising prevalence and expanded indications.
• Market share shifts: Biosimilar entrants could capture 15-25% of the market by 2030.
• Pricing pressure: Intensity depends on regional reimbursement policies; expected to compress margins gradually.

By 2028, the market could reach approximately $1.35 billion, with early biosimilar entries potentially impacting revenue streams from 2025 onward.

Investment and R&D Outlook

• R&D investments in long-acting formulations, gene therapy adjuncts, and alternative delivery pathways are increasing.
• Companies allocate roughly 12% of revenue to R&D, of which 30% targets coagulation factor development.

What Are the Challenges and Risks?

• Patent expirations threaten exclusivity.
• Biosimilar entry may lead to price erosion.
• Manufacturing complexities for recombinant proteins increase operational costs.
• Regional reimbursement barriers persist in emerging markets.

What Is the Outlook for Market Players and Stakeholders?

• Innovation: Long-acting formulations aimed at reducing dosing frequency are under clinical development.
• Expansion: Gene therapy trials could redefine treatment paradigms, impacting demand trajectory.
• Geopolitical factors, such as trade restrictions and healthcare reforms, influence regional sales.

Key Takeaways

• The coagulation factor VIIa market is set to grow steadily at a CAGR of 7.4%, reaching $1.35 billion by 2028.
• Novo Nordisk maintains dominant market share; biosimilar competition is poised to challenge pricing and market power.
• Advances in technology and indications expand growth potential but face regulatory and reimbursement hurdles.
• The long-term financial outlook hinges on innovation, patent landscapes, and development pace.

Frequently Asked Questions

1. How will biosimilar entry impact drug pricing?
Biosimilar entrants typically reduce prices by 20-40%, increasing accessibility but reducing revenue for originator companies.

2. What are the key opportunities in emerging markets?
Expanding healthcare infrastructure, government subsidies, and increasing diagnosis rates foster growth potential.

3. Are gene therapies influencing market forecasts?
Long-term gene therapies could diminish demand for recurrent recombinant therapies, introducing market phase shifts.

4. What regulatory trends should investors watch?
Rapid approvals, orphan drug designations, and flexible pathways in regions like the US and Europe could accelerate sales.

5. What are the key drivers for next-generation formulations?
Extended half-life, improved bioavailability, and reduced administration burden are primary focus areas.

---

References

1. MarketsandMarkets. (2022). Hemophilia Market by Product, End User, and Region — Global Forecast to 2028.
2. Novo Nordisk. (2022). Annual report.
3. U.S. Food and Drug Administration. (2022). Approved Hemophilia Treatments.
4. European Medicines Agency. (2022). Summary of Product Characteristics for NovoSeven RT.
5. Grand View Research. (2021). Coagulation Factor Market Size, Share & Trends Analysis.